Skip to main content

Table 1 Clinical, treatment and survival characteristics of the 21 patients with CD20-negative diffuse large B-cell lymphoma

From: CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution

Patient NO.

Age, y/Sex

HIV status

PS score

Site of involvement

Stage

Bulky disease

Serum LDH

IPI

Therapy and response for initial therapy

Out come

Survival (months)

1

68/M

-

1

LN

IIB

No

Normal

1

CHOP × 6+RT, ICE × 4,CR

AWD

117

2

33/F

-

1

Cervical

IA

No

Normal

0

CHOP × 4, CR

AND

117

3

49/F

-

1

Maxillary sinus, LN

IIB

No

Normal

0

CHOP × 5, DHAP × 4, CR

DOD

11

4

11/M

-

2

Spinal canal, Retroperitoneal

IIIB

Yes

Normal

3

Surgical resection+RT, CAV × 2 + BFM-90 × 1, PD

DOD

23

5

37/M

-

1

Retroperitoneal, LN, BM

IVB

Yes

Elevated

2

CHOP × 2,VAD × 2,MEA × 2, PR

AND

90

6

56/M

-

1

Stomach, Retroperitoneal,

IIB

No

Normal

0

CHOP × 6,ICE × 2,DHAP × 3, GEMOX × 7,Auto PBSCT, PR

DOD

33

7

54/F

-

1

Stomach

IIB

Yes

Normal

0

Gastrectomy, CHOP × 6,ICE × 2, EPOCH × 1,FC × 1, PD

DOD

13

8

73/M

-

1

LN

IA

No

Elevated

2

CHOP × 2, PD

DOD

7

9

44/M

-

1

LN

IIIA

No

Elevated

2

CHOP × 6,HD-MTX +Ara-C × 1, PD

DOD

6

10

41/M

-

2

Stomach, LN

IIA

No

Elevated

1

CHOP × 2, PD

DOD

3

11

66/M

-

1

Stomach, LN

IIB

Yes

Elevated

2

EPOCH × 6+RT, CR

AND

27

12

22/M

-

1

Liver, lung, LN, hip

IVB

No

Elevated

3

CHOP × 1,DHAP × 2, IMVP-16 × 4, PD

DOD

13

13

55/M

-

1

LN

IA

No

Normal

0

Bortezomib+EPOCH × 4, RT, CR

AND

25

14

19/F

-

1

Stomach, LN

IIA

Yes

Normal

0

Gastrectomy, CHOP × 6, CR

AND

20

15

67/M

-

1

Spleen, LN

IIIA

No

Elevated

3

CHOP × 1, ICE × 4,SD

AWD

19

16

47/F

-

1

Ileum, liver, LN,

IVA

Yes

Normal

2

Surgical resection, CHOP × 1, MAID × 2,GEMOX × 4,ESHAP × 2, PD

DOD

12

17

27/M

-

1

Mediastinum, pleural

IIA

Yes

Normal

0

Surgical resection, CHOP+IT × 6, CR

AND

15

18

83/M

-

1

Lung, rib, LN

IVA

No

Normal

3

CHOP × 3, GEMOX × 2, CR

DOD

7

19

53/M

-

1

Stomach, LN

IIIA

No

Normal

1

CHOPE × 6,GIFOX × 2,GND × 2, CR

AND

9

20

67/M

-

1

LN

IA

No

Normal

1

RT,CHOP × 2,Ara-C+DXM × 1, Ara-C+Paclitaxel × 1, PR

AWD

9

21

71/M

-

2

Kidney, sternum, vertebral, BM

IVA

Yes

Normal

3

CHOP × 2, ICE × 2, PR

DOD

7

  1. Note: -, negative; +, positive; PS, performance status; LN, lymph node; BM, bone marrow; LDH, lactate dehydrogenase; IPI, International Prognostic Index; RT, radiotherapy; CAV, cyclophosphamide, doxorubicin, vincristine; VAD, vincristine, doxorubicin, dexamethasone; MEA, mitoxantrone, etoposide, cytarabine; GEMOX, gemcitabine, oxaliplatin; GIFOX, gemcitabine, ifosfamide, oxaliplatin; GND, gemcitabine, vinorelbine, doxil; DXM, dexamethasone; MAID, mesna, doxorubicin, ifosfamide, dacarbazine; PBSCT, peripheral blood stem cell transplant; IT, intrathecal; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us